Authors: Nicholas Smedira, Randall Starling, Cleveland Clinic, Cleveland, OH, USA Background: The Heartmate® II (HM2) left ventricular assist device (LVAD) improves survival and quality of life for patients with end-stage heart failure. Whether these improved outcome measures are similarly accompanied by a reduction in unplanned hospital readmissions is unknown. We systematically evaluated the frequency, etiology, and impact of unplanned hospital readmissions following HM2 implantation Methods: Between 10/21/2004 and 12/31/2009, N=118 consecutive patients underwent HM2 implantation; N=92 were discharged. Using a prospectively maintained clinical database reasons for rehospitalizations were analyzed and destination therapy (DT) and bridge to transplant (BTT) were compared. Significant factors shown with coefficient and reliability-% of occurrence of factors in a 500 bootstrapped model.
